|
On behalf of the organising committee, it is our pleasure to invite you to attend the annual ManxBioMed conference
ManxBioMed
Annual Bio Business Conference
10-12th December 2014
Claremont Hotel, Douglas, Isle of Man
Announcement
Following the success of last year’s Conference we are pleased to confirm that this year’s event will again take place in December. The conference is an international event for those involved in biomedical sciences and biotechnology, specifically geared towards assisting companies do business on from or through the Isle of Man. The event includes investors, dealmakers, science leaders and businesses from the UK, Europe and beyond where business opportunities, latest developments and emerging technologies will be discussed. The Conference will showcase the advantages and opportunities existing on the Isle of Man for companies and organisations working in biomed and medtech industries.
Conference Programme
- Start-up Funder Event, organised and managed by a third party please contact us for futher details
- Dinner for sponsors and speakers, (invitation only) an informal dinner for key individuals in the sector with the opportunity to lead some key topics for discussion
- Full day conference, cutting edge technologies, business and research experience presented by experts in their field both businessmen and scientists
- Bun and Business, opportunity to meet delegates in a less formal setting
Conference Speakers
Our Conference programme will include sessions on: funding, regulatory compliance, CE marking approval, trial Isle medical innovation and our provisional programme includes the following speakers:
Conference Chairman, David Onions, Honorary Professor, University of Glasgow
Investor Key Note, Jim Mellon, international investor, immunotherapy, dubbed Britain’s Warren Buffett by The Daily Telegraph
Scientific Key Note, Dr Lorin Johnson, Chief Scientific Liaison, Salix, from Founding to an $8 billion Company
We are grateful that our Conference will again be Closed by our Chief Minister, The Hon Allan Bell, MHK.
Editor’s Note
ManxBioMed – The Biotech and Medical Cluster for the Isle of Man
The ManxBioMed Cluster aims to identify, select and develop global technologies & services to aid health and minimise medical suffering. It will support early stage, fast growth Companies by working closely with entrepreneurs, scientists and legislators globally. Our Cluster is based on the Isle of Man. Members work in a wide range of areas, including cost effective industry-tailored pre-clinical and clinical drug development, manufacture of medical devices, regulatory, compliance & audit as well as medical insurance. Our Members current capabilities include full commercialisation of medical innovations for increased effectiveness of precision medicine. The Isle of Man, geographically located in the heart of the British Isles, is an independent Country, having had its own Parliament for over 1000 years. It is being increasingly recognised as a location of choice for biomed Companies due to the accessible Government, educated workforce, quality of life, and tax neutrality of Companies based here. It also enables easy access to the major EU market. Joint Founder – Nik Nikitin – Personal bio: Dr Nikolai (Nik) Nikitin is an expert in clinical trial drug development and director of Clinical Accelerator, an international clinical research organisation. Joint Founder – Courtenay Heading – Personal bio: Courtenay has been instrumental in four technology start-ups since 1985, and invested in Bio Med Companies since 2000.
The Island offers a uniquely diverse economy with sectors in: precision manufacturing, financial services, e-commerce, IT, agriculture and fishing, as well as space commerce and Aircraft and Ship Registries. With regular one hour flights to London the Isle of Man enjoys ready access to major capital markets for 2nd stage capital raising and the public market, often vital for the later stage Company.
Clinical Accelerator
Clinical Accelerator is an independent European clinical trial management organization offering a broad range of clinical research services to worldwide clients in the pharmaceutical, biotechnology and medical device industries. We perform most of our studies in Eastern Europe – a region which has become a hot spot for clinical trials in the last 15-20 years, and provide access to one of the most diverse and available patient populations in the world. Clinical Accelerator’s model of operation is designed to achieve significant cost savings for our clients and to guarantee compact timelines for patient enrollment with a firm focus on the quality of our clinical trial data.
|
clinicalaccelerator.com 
You must be logged in to post a comment.